Christophe Borg
Centre Hospitalier Universitaire de Besançon(FR)Methodology and Quality of Life Unit in Oncology(FR)
Publications by Year
Research Areas
Colorectal Cancer Treatments and Studies, Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses, Colorectal and Anal Carcinomas, Gastric Cancer Management and Outcomes
Most-Cited Works
- → Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial(2019)1,630 cited
- → Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial(2005)1,237 cited
- → Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial(2021)1,198 cited
- → Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial(2012)1,159 cited
- → Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells(2010)981 cited
- → EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer